ESMO Breast Cancer 2023 Congress Coverage


 

ESMO Breast Cancer 2023 Results of Part B of SOLTI TOT-HER3 Window of Opportunity Trial: Patritumab Deruxtecan in HR+/HER2- & TNBC

307 views
May 31, 2023
Comments 0
Login to view comments. Click here to Login